Dayana Yastremska has been provisionally suspended under Article 8.3.1(c) of the 2020 Tennis Anti-Doping Programme (the “Programme”), pending determination of the charge against her at a full hearing pursuant to Article 8 of the Programme.
Ms. Yastremska, a 20-year-old player from Ukraine, provided an Out-of-Competition urine sample on 24 November 2020. That sample was sent to the World Anti-Doping Agency (“WADA”) accredited laboratory in Montreal, Canada for analysis, and was found to contain mesterolone metabolite. Mesterolone is a Non-Specified substance, which is prohibited under category S1 of the 2020 WADA Prohibited List (Anabolic Agents), and therefore is also prohibited under the Programme. Positive tests for Non-Specified Substances carry a mandatory Provisional Suspension.
On 22 December 2020, Ms. Yastremska was charged with an Anti-Doping Rule Violation under Article 2.1 of the Programme (presence of a Prohibited Substance in a Player’s Sample) and was Provisionally Suspended with effect from 7 January 2021. Ms. Yastremska had (and retains) the right to apply to the Chair of the Independent Tribunal convened to hear her case why the Provisional Suspension should not be imposed, but has chosen not to exercise that right to date.
Note to Editors:
The Tennis Anti-Doping Programme applies to all players competing at Grand Slam tournaments and events sanctioned by the ITF, ATP and WTA. Players are tested for substances prohibited by the World Anti-Doping Agency and, upon finding that an Anti-Doping Rule Violation has been committed, sanctions are imposed under the Programme in compliance with the requirements of the World Anti-Doping Code. More information on the Programme, sanctions, statistics, and related matters can be found at itftennis.com/antidoping
